Pieris Pharmaceuticals Inc.

12/16/2024 | Press release | Distributed by Public on 12/16/2024 18:43

Initial Statement of Beneficial Ownership (Form 3)

Ownership Submission
FORM 3
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104 Estimated average burden hours per response... 0.5
(Print or Type Responses)
1. Name and Address of Reporting Person *
Martini Jeffrey S
2. Date of Event Requiring Statement (Month/Day/Year)
12/13/2024 		3. Issuer Name and Ticker or Trading Symbol
PALVELLA THERAPEUTICS, INC. [PVLA]
(Last) (First) (Middle)
C/O PALVELLA THERAPEUTICS, INC., 125 STRAFFORD AVENUE, SUITE 360 		4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
Chief Scientific Officer
5. If Amendment, Date Original Filed (Month/Day/Year)
(Street)
WAYNE, PA 19087 		6. Individual or Joint/Group Filing (Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City) (State) (Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4) 		2. Amount of Securities Beneficially Owned
(Instr. 4) 		3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5) 		4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4) 		2. Date Exercisable and Expiration Date
(Month/Day/Year) 		3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4) 		4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5) 		6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy) (1) 10/11/2030 Common Stock 32,272 $9.08 D
Stock Option (right to buy) (2) 02/22/2033 Common Stock 10,213 $9.79 D
Stock Option (right to buy) (2) 02/22/2033 Common Stock 18,541 $9.79 D
Stock Option (right to buy) (3) 05/27/2034 Common Stock 13,281 $7.53 D
Stock Option (right to buy) (3) 05/27/2034 Common Stock 6,606 $7.53 D

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Martini Jeffrey S
C/O PALVELLA THERAPEUTICS, INC.
125 STRAFFORD AVENUE, SUITE 360
WAYNE, PA 19087 		Chief Scientific Officer

Signatures

/s/ Kathleen A. McGowan, Attorney-in-Fact 12/16/2024
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) The stock option is fully vested.
(2) The stock option vests in equal monthly installments over a forty-eight month period. The option was granted on February 23, 2023.
(3) The stock option vests in equal monthly installments over a forty-eight month period. The option was granted on May 28, 2024.
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.